|
|
|
|
| LEADER |
06546cam a2200781Ia 4500 |
| 001 |
000585083 |
| 003 |
OCoLC |
| 005 |
20180621115010.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
080205s2008 ne ob 001 0 eng d |
| 020 |
|
|
|a 9780080557229
|q (electronic bk.)
|
| 020 |
|
|
|a 0080557228
|q (electronic bk.)
|
| 020 |
|
|
|a 0123736013
|q (electronic bk.)
|
| 020 |
|
|
|a 9780123736017
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)191820152
|z (OCoLC)271575894
|z (OCoLC)648331501
|z (OCoLC)808677258
|z (OCoLC)871800990
|z (OCoLC)904806611
|z (OCoLC)1004351421
|z (OCoLC)1030306764
|
| 040 |
|
|
|a Sistema de Bibliotecas de la Universidad de Costa Rica
|
| 050 |
|
4 |
|a QR201.A37
|b H58 2008eb
|
| 072 |
|
7 |
|a MED
|x 022020
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 039020
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.979206
|2 22
|
| 245 |
0 |
0 |
|a HIV-I : molecular biology and pathogenesis :
|b clinical applications /
|c edited by Kuan-Teh Jeang.
|
| 246 |
3 |
|
|a Clinical applications
|
| 250 |
|
|
|a 2nd ed. /
|b edited by J. Thomas Aug., Ferid Murad and Kuan-Teh Jeang.
|
| 260 |
|
|
|a Amsterdam ;
|a Boston :
|b Elsevier/Academic Press,
|c 2008.
|
| 300 |
|
|
|a 1 online resource (593 pages).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in pharmacology ;
|v vol. 56
|
| 500 |
|
|
|a Previous edition: 2000.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 520 |
|
|
|a Although it is one of the most-widely studied viruses, many mysteries still remain about HIV. Covering the latest advances and challenges associated with clinical application of new antiviral drugs and vaccines, this revised edition is a companion to Murad:HIV-1: Molecular Biology and Pathogenesis, 2E. Leading investigators in HIV research present a timely picture of the molecular mechanisms which guide HIV-1 expression and replication and provide the most current clinical strategies for combating this virus. * The latest developments in HIV-vaccine research * New concepts in the discovery and design of novel anti-HIV drugs.
|
| 505 |
0 |
|
|a Front Cover; HIV-1: Molecular Biology and Pathogenesis; Copyright Page; Contents; Contributors; Preface written by Robin A. Weiss; A. HIV Types (HIV-1 and HIV-2); B. Genotype Classification of HIV-1s; C. HIV-2: Genotype Classification and Geographic Distribution; A. Global HIV-1 Variability; B. HIV-1 Variants in Asia; C. Other HIV-1 Variants of Geographical Relevance; D. Emergence og HIV-1 Recombinants Worldwide; A. Phylogenetic Sequeuce Analysis; B. Alternative Methods (Heteroduplex Mobility Assay and Serotyping); VI. Origin of HIVs and Genesis of HIV-1 Pandemic.
|
| 505 |
8 |
|
|a A. HIV/AIDS as a ""Zoonosis""B. Dating the Origin of Pandemic HIV-1 Strains; A. HIV-1 Subtypes and Disease Progression; B. HIV-1 Dual Infection, Superinfection, and Recombination; C. Biological Implications of Recombination; Acknowledgments; References; B. Nonnucleoside Reverse Transcriptase Inhibitors; C. Protease Inhibitors; A. Initiation of Therapy; B. Initial Regimen; C. Long-Term Management; D. Resistance; E. Drugs in Development; IV. Conclusion; References; A. Protective Role of HIV-1-Specific T-Cell Responses; B. Kinetics of HIV-1-Specific T-Cell Responses in Primary Infection.
|
| 505 |
8 |
|
|a C. Phenotypic and Functional Profiles of HIV-1-Specific CD4 and CD8 T-Cell ResponsesD. Phenotype; E. Function; F. Specificity and Breadth of HIV-1-Specific T-Cell Responses; References; II. Background; III. Inhibition of Viral Attachment; A. gp120 Inhibitors; B. Targeting CD4; IV. Chemokine Receptors in HIV Infection; V. Targeting Coreceptor Binding; A. CXCR4 Inhibition; B. Targeting CCR5 for HIV Therapy; VI. Fusion Inhibitors; A. Targeting gp41; B. Inhibition of Membrane Fusion; VII. Resistance to Inhibitors of Viral Entry; VIII. Use Entry Inhibitors as Microbicides; References.
|
| 505 |
8 |
|
|a B. Mechanism of HIV-1 RT DNA Polymerase ActivityA. Mechanisms of NRTI Inhibition; B. NRTI Approved for Clinical Use; C. Investigational NRTI; D. HIV-1 Resistance to NRTIs; V. Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs); A. Mechanisms of NNRTI Inhibition; B. NNRTI Approved for Clinical Use; C. Investigational NNRTI; D. HIV-1 Resistance to NNRTIs; E. Interactions Between NNRTI and NRTI Resistance Mutations; F. Use of NNRTI as Microbicides; VI. Other Inhibitors of HIV-1 RT; A. Inhibitors of HIV-1 RT RNH; B. Inhibitors of HIV-1 RT Dimerization.
|
| 505 |
8 |
|
|a C. Inhibitors of the Initiation of Reverse TranscriptionD. RT-Directed Mutagenic Inducers; VII. Conclusion; Acknowledgments; References; A. Mechanism of Action of PIs; B. Protease Structures and Substrate-Based Inhibitors; C. Design of Symmetry-Based Inhibitors; D. Structure-Based PIs; A. Emergence of Drug Resistance to PIs; B. Primary and Secondary Mutations; C. Active site Mutants; D. Nonactive Site Mutants; E. Cleavage Site Mutants; F. Noncleavage Site Mutants; G. Insertions in Gag-Pol Polyproteins; VII. PIs with Activity Against Drug-Resistant HIV-1.
|
| 546 |
|
|
|a Text in English.
|
| 590 |
|
|
|a Elsevier
|b ScienceDirect Book Series
|
| 650 |
|
0 |
|a HIV infections
|x Molecular aspects.
|
| 650 |
|
0 |
|a HIV infections
|x Pathogenesis.
|
| 650 |
|
0 |
|a HIV infections
|x Treatment.
|
| 650 |
|
0 |
|a AIDS vaccines.
|
| 650 |
|
7 |
|a MEDICAL
|x AIDS & HIV.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x AIDS & HIV.
|2 bisacsh
|
| 650 |
|
7 |
|a AIDS vaccines.
|2 fast
|0 (OCoLC)fst00794025
|
| 650 |
|
7 |
|a HIV infections
|x Pathogenesis.
|2 fast
|0 (OCoLC)fst00949893
|
| 650 |
|
7 |
|a HIV infections
|x Treatment.
|2 fast
|0 (OCoLC)fst00949907
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a August, J. Thomas.
|
| 700 |
1 |
|
|a Murad, Ferid.
|
| 700 |
1 |
|
|a Jeang, Kuan-Teh.
|
| 776 |
0 |
8 |
|i Print version:
|t HIV-I : molecular biology and pathogenesis.
|b 2nd ed.
|d Amsterdam ; Boston : Elsevier/Academic Press, 2008
|z 9780123736017
|z 0123736013
|w (OCoLC)174129525
|
| 830 |
|
0 |
|a Advances in pharmacology ;
|v vol. 56.
|
| 856 |
4 |
0 |
|u https://sciencedirect.proxyucr.elogim.com/bookseries/advances-in-pharmacology/vol/56/suppl/C
|
| 994 |
|
|
|a 92
|b SIBDI
|
| 019 |
|
|
|a 271575894
|a 648331501
|a 808677258
|a 871800990
|a 904806611
|a 1004351421
|a 1030306764
|
| 029 |
1 |
|
|a AU@
|b 000042546146
|
| 029 |
1 |
|
|a DEBSZ
|b 405317808
|
| 029 |
1 |
|
|a DEBSZ
|b 430464274
|
| 049 |
|
|
|a MAIN
|
| 938 |
|
|
|a 123Library
|b 123L
|n 43092
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL330114
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10206152
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 216912
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 2772554
|